ABT vs BBOT · P/E 25, rev $44.33B vs $610.4M cap
Abbott Laboratories (ABT) versus BridgeBio Oncology Therapeutics, Inc. (BBOT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
BBOT does not have a complete income-statement cache yet.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. BBOT currently screens at market cap $610.4M.
Not investment advice. Open the ABT and BBOT stock pages for the full models.
Not investment advice.